Amarin Corp Plcuk (AMRN) Cost of Revenue (2013 - 2026)
Amarin Corp Plcuk (AMRN) reported Cost of Revenue of $27.4 million for Q1 2026, up 270.57% year-over-year from $7.4 million in Q1 2025, and down 63.12% quarter-over-quarter from $74.2 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Cost of Revenue (2013 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 14 years of Cost of Revenue data on file, last reported at $27.4 million in Q1 2026.
- Cost of Revenue for Q1 2026 came in at $27.4 million, up 270.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $126.7 million (up 133.69% YoY), and the FY2025 annual result was $92.8 million, up 131.08% from the prior year.
- Cost of Revenue declined to $27.4 million in Q1 2026 per AMRN's latest filing, from $74.2 million in the prior quarter.
- Over five years, Cost of Revenue peaked at $74.2 million in Q4 2025 and troughed at -$15.3 million in Q4 2023.
- A 5-year average of $22.3 million and a median of $23.6 million in 2023 frame the typical range for Cost of Revenue.
- The sharpest annual moves came in 2023 and 2025: Cost of Revenue plunged 143.72% in 2023, then surged 601.88% in 2025.
- A 5-year view of Cost of Revenue shows it stood at $35.0 million in 2022, then slumped by 143.72% to -$15.3 million in 2023, then surged by 169.05% to $10.6 million in 2024, then surged by 601.88% to $74.2 million in 2025, then tumbled by 63.12% to $27.4 million in 2026.
- Business Quant data shows AMRN's Cost of Revenue at $27.4 million in Q1 2026, $74.2 million in Q4 2025, and $2.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 2.53 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 3.58 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 8.11 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 4.22 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 4.20 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 2.74 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 1.45 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 3.55 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 3.42 Bn |
| 10 | Amarin Corp Plcuk | 6.77 Bn | 6.59 Bn | 17.77 Mn | 27.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.36 Mn |
| Mar 31, 2026 | 27.36 Mn |
| Dec 31, 2025 | 74.20 Mn |
| Dec 31, 2025 | 74.20 Mn |
| Sep 30, 2025 | 2.72 Mn |
| Sep 30, 2025 | 2.72 Mn |
| Jun 30, 2025 | 22.38 Mn |
| Jun 30, 2025 | 22.38 Mn |
| Mar 31, 2025 | 7.38 Mn |
| Mar 31, 2025 | 7.38 Mn |
| Dec 31, 2024 | 10.57 Mn |
| Dec 31, 2024 | 10.57 Mn |
| Sep 30, 2024 | 26.02 Mn |
| Sep 30, 2024 | 26.02 Mn |
| Jun 30, 2024 | 10.22 Mn |
| Jun 30, 2024 | 10.22 Mn |
| Mar 31, 2024 | 24.62 Mn |
| Mar 31, 2024 | 24.62 Mn |
| Dec 31, 2023 | -15.31 Mn |
| Dec 31, 2023 | -15.31 Mn |